An interventional study of remimazolam and Propofol in Hypoxia, Hysteroscopy and Overweight or Obesity, sponsored by RenJi Hospital. Recruiting at 1 site in China. Open to female participants aged 20 Years to 50 Years. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by RenJi Hospital · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Hypoxia by RenJi Hospital — 5 open to participants now, 5 under way, none of them phase 3. Hypoxia · RenJi Hospital.
Among the 14 studies in Hypoxia by RenJi Hospital, this one is the 9th largest by planned enrollment, is one of 2 that started in 2024, is one of 14 with no phase, and was the 14th registered.
1,081 studies on the registry are indexed under Hypoxia; 213 are open to participants now.
Browse Hypoxia studies →5 of the 14 studies in Hypoxia by RenJi Hospital are open now, in 1 country. Recruiting first, the newest first:
RenJi Hospital · Sites in China
Ages 18–60 · Healthy volunteers
RenJi Hospital · Sites in China
Ages 18–70
RenJi Hospital · Sites in China
Ages 18–80
RenJi Hospital · Sites in China
Ages 20–50 · Women only
By country, each count listing its studies:
Of the 124 Hypoxia studies recruiting now, 52 (42%) set no upper age limit and 46 (37%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 20 Years to 50 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 2 started in 2024.
This study's planned enrollment of 600 is above the median of 45 across 771 interventional studies indexed under Hypoxia.
Median enrollment 980 across the 14 interventional studies. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
RenJi Hospital is the lead sponsor of 551 studies on the registry; 248 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Hypoxia by RenJi Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Hypoxia is a common adverse event during sedated hysteroscopy for assisted reproduction, and it is more likely to occur in overweight or obese patients. In sedated gastroscopy, the incidence of hypoxia with remimazolam is lower than that with propofol. The present study is a single-center, randomized, single-blind, controlled clinical trial. Overweight or obese patients undergoing sedated hysteroscopy for diagnosis and treatment, with ASA grade I or II, were selected as subjects and randomly divided into an experimental group and a control group, with 300 subjects in each group. Sedation induction and maintenance are performed using remimazolam or propofol combined with remifentanil, respectively, to compare the incidence of severe hypoxia during surgery between the two groups of patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In this group, participants are sedated with remimazolam and remifentanil.
Drug: remimazolam
In this group, participants are sedated with propofol and remifentanil.
Drug: Propofol
in this group,patients are treated with remimazolam and remifentanil for reduced sedation.
in this group,patients are treated with propofol and remifentanil for reduced sedation.
The incidence of severe hypoxia
SpO2\<75% or 75%≤ SpO2\<90% for≥60s
Time frame: people will be followed for the duration of hospital stay,an expected average about 2 hours
The incidence of hypoxia
75%≤ SpO2% \<90% for\<60s
Time frame: people will be followed for the duration of hospital stay,an expected average about 2 hours
The incidence of sub-clinical respiratory depression
90%≤ SpO2\<95%
Time frame: people will be followed for the duration of hospital stay,an expected average about 2 hours
The incidence of other adverse events
Other adverse events recorded by tools proposed by the World Society of Intravenous Anesthesia International Sedation Task Force
Time frame: people will be followed for the duration of hospital stay,an expected average about 2 hours
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2024 (actual). Primary completion is estimated for Feb 2026, 25 months after the start.
Of 324 non-industry interventional studies with no phase under Hypoxia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 27. This study's planned 25 months is above that.
Counting every sponsor, half of 354 studies reached it within 12 months; a quarter within 3 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Remimazolam